Scott D J, Parkes A T, Ponchel F, Cummings M, Poola I, Speirs V
Leeds Institute of Molecular Medicine, University of Leeds, Leeds, UK.
Int J Oncol. 2007 Sep;31(3):557-65. doi: 10.3892/ijo.31.3.557.
Tamoxifen resistance (TAMr) in breast cancer is a serious clinical dilemma, with no satisfactory explanation. We hypothesised that changes in the expression of steroid hormone receptors (ERalpha, ERbeta), their downstream target genes (PR, pS2) and their associated co-regulators (AIB-1, SRC-1, SRA, NCoR-1, SMRT and REA) could be related to the acquisition of TAMr. To test this hypothesis, we developed in vitro TAMr cell line models by continuous exposure of MCF-7 cells to 4-hydroxytamoxifen (4-HT) over 12 (MCF-7MMU1) and 21 (MCF-7MMU2) months, respectively and examined the expression of the above by Western blotting and immunohistochemistry. In addition, we further examined the changes in global gene expression in TAMr cells in comparison with TAM-sensitive cells by microarray analysis. We report here that acquisition of TAMr is associated with changes in the expression of PR, pS2 and several co-activators, but not ERs. In addition, genes associated with cell cycle, cell adhesion and extracellular matrix, were up-regulated while those associated with apoptosis or growth factors/hormones were down-regulated. Based on our results, it appears that increased co-activator expression, in concert with alterations in genes associated with controlling cell proliferation and survival contribute to TAMr in breast cancer.
乳腺癌中的他莫昔芬耐药(TAMr)是一个严重的临床难题,目前尚无令人满意的解释。我们推测,甾体激素受体(ERα、ERβ)、其下游靶基因(PR、pS2)及其相关共调节因子(AIB-1、SRC-1、SRA、NCoR-1、SMRT和REA)表达的变化可能与TAMr的获得有关。为了验证这一假设,我们通过将MCF-7细胞分别连续暴露于4-羟基他莫昔芬(4-HT)12个月(MCF-7MMU1)和21个月(MCF-7MMU2),建立了体外TAMr细胞系模型,并通过蛋白质印迹法和免疫组织化学检测上述指标的表达。此外,我们通过微阵列分析进一步检测了TAMr细胞与TAM敏感细胞相比整体基因表达的变化。我们在此报告,TAMr的获得与PR、pS2和几种共激活因子的表达变化有关,但与ERs无关。此外,与细胞周期、细胞黏附和细胞外基质相关的基因上调,而与凋亡或生长因子/激素相关的基因下调。基于我们的结果,似乎共激活因子表达的增加,与控制细胞增殖和存活相关基因的改变共同导致了乳腺癌中的TAMr。